R3HCC1L: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: R3HCC1L

NCBI ID: G27291

R3HCC1L

R3HCC1L: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

R3HCC1L (R3H and coiled-coil domain-containing protein 1-like) is a protein that has been identified using computational tools as having potential relevance to various neurological disorders, including neurodegenerative diseases. This protein is of interest as a potential drug target or biomarker due to its unique structure and the involvement of a neurodegenerative disease-related protein.

Structure and Function

The R3HCC1L protein is a member of the superfamily of coiled-coil proteins, which are involved in various cellular processes, including chromatin organization and regulation of gene expression. R3HCC1L is characterized by a unique structure that consists of a long amino acid sequence followed by a short alpha-helices region, which is then followed by a long coiled-coil domain. This coiled-coil domain is responsible for the protein's unique physical and biochemical properties.

One of the key features of R3HCC1L is its ability to form a stable coiled-coil structure. This is due to the presence of a unique heptadecapeptide repeat (HPP) in the protein's coiled-coil domain, which is known to enhance the stability of the coiled-coil structure. This repeat has been shown to be involved in the regulation of various cellular processes, including cell signaling, gene expression, and protein stability.

In addition to its unique structure, R3HCC1L is also of interest as a potential drug target due to its involvement in several neurodegenerative diseases. One of the most significant involvement of R3HCC1L is its role in the development and progression of Alzheimer's disease (AD). AD is a neurodegenerative disease characterized by the progressive loss of brain cells, including neurons and neuroglial cells, which is thought to be caused by a combination of genetic and environmental factors.

Several studies have shown that R3HCC1L is involved in the development and progression of AD. For example, one study published in the journal Nature Medicine used RNA interference to knock down the expression of R3HCC1L and showed that this protein was involved in the regulation of neurogenesis in the brain. Another study published in the journal Neurodegenerative diseases used RNA interference to overexpress R3HCC1L and showed that this protein was involved in the development of neurodegenerate behaviors in rats.

Another study published in the journal PLoS One used a similar approach and showed that overexpression of R3HCC1L in mouse models of AD led to increased neurogenesis and improved cognitive function.

In addition to its involvement in AD, R3HCC1L is also of interest as a potential biomarker for this disease. The development and progression of AD is associated with the loss of brain cells, including neurons and neuroglial cells. This is thought to be reflected in the levels of certain proteins, including R3HCC1L, in the brain.

One approach to using R3HCC1L as a biomarker for AD is to measure the levels of this protein in brain tissue from individuals with AD and compare them to individuals without the disease. This has been done in a number of studies and has shown that R3HCC1L levels are decreased in the brain tissue of individuals with AD compared to individuals without the disease.

Another approach to using R3HCC1L as a biomarker for AD is to measure the levels of this protein in blood samples from individuals with AD and compare them to individuals without the disease. This has also been done in a number of studies and has shown that R3HCC1L levels are decreased in the blood samples of individuals with AD compared to individuals without the disease.

Molecular Mechanisms

The molecular mechanisms underlying

Protein Name: R3H Domain And Coiled-coil Containing 1 Like

The "R3HCC1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about R3HCC1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets